Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
CorrigendaCorrigenda
Open Access

Corrigenda

Anticancer Research June 2022, 42 (6) 3231-3232;
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Vol. 42, No. 4, page 2055 Figure 1 should be:

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Vol. 42, No. 4, page 2055, right column, 6th line should read:

125 events) for grade 1, 64.3% (27 of 42) for grade 2, 38.7%

Vol. 42, No. 4, page 2056, right column, 5th line should read:

was started on the 7th day rather than on the 12th day of

Vol. 42, No. 4, page 2056, right column, 22nd line should read:

149 events of 246 AEs, the onset timing and duration of

Vol. 42, No. 4, page 2059, left column, 3rd and 4th line should read:

of 246 AEs occurred with different onset timings, all of

which were predictable AE items. Among those AEs, 149

Volume 42, no. 5, page 2791, the names of the second and fifth Author should read:

YOICHI HAMAI and MANATO OHSAWA

  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Previous
Back to top

In this issue

Anticancer Research: 42 (6)
Anticancer Research
Vol. 42, Issue 6
June 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Corrigenda
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Corrigenda
Anticancer Research Jun 2022, 42 (6) 3231-3232;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Corrigenda
Anticancer Research Jun 2022, 42 (6) 3231-3232;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy
  • Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire